Short description
Bioheart is a biotech company that focuses on the development of effective cell technologies to treat cardiovascular diseases.
Description
Bioheart, Inc. is dedicated to advancing the field of regenerative medicine by offering the highest quality technology, cellular treatments and training. Specific to biotechnology, Bioheart, Inc. specializes in the discovery, development and commercialization of autologous cellular therapies that treat a wide variety of degenerative diseases.
Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry by delivering stem cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, chronic and acute heart damage, peripheral vascular disease and other issues. Bioheart's goals are to improve a patient’s quality of life by regenerating their damaged tissue, when possible, and by reducing health care costs and hospitalizations. Bioheart’s leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.
Last funding
Nopepepe
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Sunrise, Florida, United States, North America
Founded on
January 1, 1999
Exited on
May 15, 2009
Went public on
May 15, 2009
Delisted on
August 27, 2015
Stock symbol
BHRT
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$1230 - 4560
Sign in for full access
Investors
No Way, Noaccess, Noaccess, Noaccessforu, Uh Ohhhh, Noaccess
Sign in for full access
Founders
Howard Leonhardt, William P. Murphy